Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""RITONAVIR"" wg kryterium: Temat


Tytuł :
Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients.
Autorzy :
Kalantari S; Antimicrobial Resistance Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran.; Department of Infectious Diseases, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Fard SR; Antimicrobial Resistance Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran.
Maleki D; Antimicrobial Resistance Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran.; Department of Infectious Diseases, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Taher MT; Antimicrobial Resistance Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran.; Department of Infectious Diseases, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Yassin Z; Antimicrobial Resistance Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran.; Department of Infectious Diseases, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Alimohamadi Y; Pars Advanced and Minimally Invasive Medical Manners Research Center, Pars Hospital, Iran University of Medical Sciences, Tehran, Iran.
Minaeian S; Antimicrobial Resistance Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran.
Pokaż więcej
Źródło :
Journal of medical virology [J Med Virol] 2021 Dec; Vol. 93 (12), pp. 6557-6565. Date of Electronic Publication: 2021 Jul 28.
Typ publikacji :
Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antiviral Agents/*therapeutic use
Atazanavir Sulfate/*therapeutic use
COVID-19/*drug therapy
Heterocyclic Compounds, 3-Ring/*therapeutic use
Hydroxychloroquine/*therapeutic use
Lopinavir/*therapeutic use
Oxazines/*therapeutic use
Piperazines/*therapeutic use
Pyridones/*therapeutic use
Ritonavir/*therapeutic use
Antiviral Agents/administration & dosage ; Atazanavir Sulfate/administration & dosage ; COVID-19/pathology ; Drug Combinations ; Drug Therapy, Combination ; Female ; Heterocyclic Compounds, 3-Ring/administration & dosage ; Humans ; Hydroxychloroquine/administration & dosage ; Lopinavir/administration & dosage ; Male ; Middle Aged ; Oxazines/administration & dosage ; Piperazines/administration & dosage ; Pyridones/administration & dosage ; Ritonavir/administration & dosage ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Implications of phase solubility/miscibility and drug-rich phase formation on the performance of co-amorphous materials: The case of Darunavir co-amorphous materials with Ritonavir and Indomethacin as co-formers.
Autorzy :
Shete S; Department of Pharmaceutical Quality Assurance, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal 576104, India.
Reddy SC; Department of Pharmaceutical Quality Assurance, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal 576104, India.
Lakshman YD; Department of Pharmaceutical Quality Assurance, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal 576104, India.
Vullendula SKA; Department of Pharmaceutical Quality Assurance, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal 576104, India.
Mehta CH; Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal 576104, India.
Nayak UY; Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal 576104, India.
Dengale S; Department of Pharmaceutical Quality Assurance, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal 576104, India; Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, Changsari 781101, India. Electronic address: .
Pokaż więcej
Źródło :
International journal of pharmaceutics [Int J Pharm] 2021 Oct 25; Vol. 608, pp. 121119. Date of Electronic Publication: 2021 Sep 21.
Typ publikacji :
Journal Article
MeSH Terms :
Pharmaceutical Preparations*
Ritonavir*
Darunavir ; Indomethacin ; Solubility
Czasopismo naukowe
Tytuł :
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.
Autorzy :
Arabi YM; Intensive Care Department, Ministry of the National Guard-Health Affairs, ICU 1425, P.O. Box 22490, Riyadh, 11426, Kingdom of Saudi Arabia. .; King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia. .; King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia. .
Gordon AC; Division of Anaesthetics, Pain Medicine and Intensive Care, Imperial College London, London, UK.; Intensive Care Unit, Imperial College Healthcare NHS Trust, London, UK.
Derde LPG; Intensive Care Center, University Medical Center Utrecht, Utrecht, The Netherlands.; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
Nichol AD; University College Dublin Clinical Research Centre At St Vincents University Hospital, Dublin, Ireland.; The Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, Australia.; The Alfred Hospital, Melbourne, Australia.
Murthy S; Department of Pediatrics, University of British Columbia, Vancouver, Canada.
Beidh FA; Division of Anaesthetics, Pain Medicine and Intensive Care, Imperial College London, London, UK.
Annane D; Department of Intensive Care, Hôpital Raymond Poincaré (APHP), 92380, Garches, France.; Laboratory of Infection and Inflammation, U1173, School of Medicine Simone Veil, University Versailles Saint Quentin and University Paris Saclay, INSERM, 78423, Montigny le Bretonneux, France.; FHU SEPSIS (Saclay and Paris Seine Nord Endeavour To PerSonalize Interventions for Sepsis) and RHU RECORDS (Rapid rEcognition of CORticosteroiD Resistant Or Sensitive Sepsis), ANR-18-RHUS60004, 92380, Garches, France.
Swaidan LA; King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia.; King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia.; Pharmaceutical Care Services, Ministry of National Guard Health Affairs, Riyadh, Kingdom of Saudi Arabia.
Beane A; Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
Beasley R; Medical Research Institute of New Zealand, Wellington, New Zealand.
Berry LR; Berry Consultants, Austin, TX, USA.
Bhimani Z; St. Michael's Hospital Unity Health Toronto, Toronto, Canada.
Bonten MJM; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.; Department of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Bradbury CA; Faculty of Health Sciences, University of Bristol, Bristol, UK.; Bristol Hematology and Oncology Centre, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
Brunkhorst FM; Anesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany.
Buxton M; Global Coalition for Adaptive Research, San Francisco, CA, USA.
Buzgau A; Monash University, Melbourne, Australia.
Cheng A; Monash University, Melbourne, Australia.; Department of Infectious Diseases, Alfred Health, Melbourne, Australia.
De Jong M; Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Detry MA; Berry Consultants, Austin, TX, USA.
Duffy EJ; Infectious Disease, Auckland City Hospital, Auckland, New Zealand.
Estcourt LJ; NHS Blood and Transplant, Oxford, UK.; Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Fitzgerald M; Berry Consultants, Austin, TX, USA.
Fowler R; University of Toronto, Toronto, ON, Canada.; Sunnybrook Health Sciences Centre, Toronto, Canada.; Canadian Critical Care Trials Group, Toronto, Canada.
Girard TD; UPMC Health System, Pittsburgh, PA, USA.; University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Goligher EC; Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Canada.
Goossens H; University of Antwerp, Wilrijk, Belgium.
Haniffa R; National Intensive Care Surveillance-Mahidol Oxford Research Unit, Colombo, Sri Lanka.; Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.; Critical Care Department, University College Hospital, London, UK.
Higgins AM; The Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, Australia.
Hills TE; Medical Research Institute of New Zealand, Wellington, New Zealand.; Auckland District Health Board, Auckland, New Zealand.
Horvat CM; UPMC Health System, Pittsburgh, PA, USA.; University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA.
Huang DT; UPMC Health System, Pittsburgh, PA, USA.; University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
King AJ; University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Lamontagne F; Université de Sherbrooke, Sherbrooke, Canada.; Centre de Recherche du CHU de Sherbrooke, Sherbrooke, Canada.
Lawler PR; University of Toronto, Toronto, ON, Canada.; Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Canada.; Peter Munk Cardiac Centre at University Health Network, Toronto, Canada.
Lewis R; Berry Consultants, Austin, TX, USA.; Harbor-UCLA Medical Center, Torrance, CA, USA.
Linstrum K; UPMC Health System, Pittsburgh, PA, USA.; University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Litton E; Intensive Care Unit, Fiona Stanley Hospital, Perth, Australia.; Intensive Care Unit, St. John of God Hospital Subiaco, Perth, Australia.; School of Medicine, University of Western Australia, Perth, Australia.
Lorenzi E; Berry Consultants, Austin, TX, USA.
Malakouti S; Computer Science, University of Pittsburgh, Pittsburgh, PA, USA.
McAuley DF; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK.; Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, Northern Ireland, UK.
McGlothlin A; Berry Consultants, Austin, TX, USA.
Mcguinness S; Medical Research Institute of New Zealand, Wellington, New Zealand.; Monash University, Melbourne, Australia.; Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland, New Zealand.
McVerry BJ; UPMC Health System, Pittsburgh, PA, USA.; University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Montgomery SK; UPMC Health System, Pittsburgh, PA, USA.; University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Morpeth SC; Microbiology Laboratory, Middlemore Hospital, Auckland, New Zealand.
Mouncey PR; Clinical Trials Unit, Intensive Care National Audit and Research Centre, London, UK.
Orr K; Pharmacy Department, Fiona Stanley Hospital, Perth, Australia.
Parke R; Medical Research Institute of New Zealand, Wellington, New Zealand.; Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland, New Zealand.; School of Nursing, The University of Auckland, Auckland, New Zealand.
Parker JC; The Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, Australia.
Patanwala AE; School of Pharmacy, University of Sydney, Sydney, Australia.; Department of Pharmacy, Royal Prince Alfred Hospital, Sydney, Australia.
Rowan KM; Intensive Care National Audit and Research Centre (ICNARC), London, UK.
Santos MS; St. Michael's Hospital Unity Health Toronto, Toronto, Canada.
Saunders CT; Berry Consultants, Austin, TX, USA.
Seymour CW; UPMC Health System, Pittsburgh, PA, USA.; University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Shankar-Hari M; Critical Care Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK.; School of Immunology and Microbial Sciences, King's College London, London, UK.
Tong SYC; Victorian Infectious Diseases Service, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.; Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Turgeon AF; Division of Critical Care Medicine, Department of Anesthesiology and Critical Care Medicine, Laval University, Quebec City, QC, Canada.; Population Health and Optimal Health Practices Research Unit, Trauma-Emergency-Critical Care Medicine, CHU de Québec-Université Laval Research Center, Quebec City, QC, Canada.
Turner AM; Medical Research Institute of New Zealand, Wellington, New Zealand.
Van de Veerdonk FL; Department of Internal Medicine, Radboudumc, Nijmegen, The Netherlands.
Zarychanski R; Critical Care Department, University of Manitoba, Winnipeg, Canada.
Green C; The Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, Australia.
Berry S; Berry Consultants, Austin, TX, USA.
Marshall JC; St. Michael's Hospital Unity Health Toronto, Toronto, Canada.; Department of Surgery, University of Toronto, Toronto, Canada.
McArthur C; Department of Critical Care Medicine, Auckland City Hospital, Auckland, New Zealand.
Angus DC; UPMC Health System, Pittsburgh, PA, USA.; University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Webb SA; The Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, Australia.; Intensive Care Unit, St. John of God Hospital Subiaco, Perth, Australia.
Pokaż więcej
Corporate Authors :
REMAP-CAP Investigators
Źródło :
Intensive care medicine [Intensive Care Med] 2021 Aug; Vol. 47 (8), pp. 867-886. Date of Electronic Publication: 2021 Jul 12.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
COVID-19*/drug therapy
Ritonavir*/therapeutic use
Adult ; Antiviral Agents/therapeutic use ; Bayes Theorem ; Critical Illness ; Drug Combinations ; Humans ; Hydroxychloroquine/therapeutic use ; Lopinavir/therapeutic use ; SARS-CoV-2
SCR Protocol :
COVID-19 drug treatment
Czasopismo naukowe
Tytuł :
Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19: a disproportionality analysis of U.S. food and drug administration adverse event reporting system (FAERS) data.
Autorzy :
Tang H; Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, FL, USA. .
Zhou L; Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina At Chapel Hill, Chapel Hill, NC, USA.
Li X; Institute for Drug Evaluation, Peking University Health Science Center, Beijing, China.
Kinlaw AC; Division of Pharmaceutical Outcome and Policy, University of North Carolina School of Pharmacy, Chapel Hill, NC, USA.; Cecil G. Sheps Center for Health Services Research, University of North Carolina At Chapel Hill, Chapel Hill, NC, USA.
Yang JY; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina At Chapel Hill, Chapel Hill, NC, USA.
Moon AM; Center for Gastrointestinal Biology and Disease, School of Medicine, University of North Carolina At Chapel Hill, Chapel Hill, NC, USA.; Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina At Chapel Hill, Chapel Hill, NC, USA.
Barnes EL; Center for Gastrointestinal Biology and Disease, School of Medicine, University of North Carolina At Chapel Hill, Chapel Hill, NC, USA.; Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina At Chapel Hill, Chapel Hill, NC, USA.
Wang T; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina At Chapel Hill, Chapel Hill, NC, USA.
Pokaż więcej
Źródło :
International journal of clinical pharmacy [Int J Clin Pharm] 2021 Aug; Vol. 43 (4), pp. 1116-1122. Date of Electronic Publication: 2021 Jul 30.
Typ publikacji :
Journal Article
MeSH Terms :
Anti-HIV Agents/*toxicity
COVID-19/*complications
Chemical and Drug Induced Liver Injury/*etiology
HIV Infections/*complications
Lopinavir/*toxicity
Ritonavir/*toxicity
Adverse Drug Reaction Reporting Systems ; Aged ; Anti-HIV Agents/therapeutic use ; Chemical and Drug Induced Liver Injury/epidemiology ; Drug Combinations ; Female ; HIV Infections/virology ; Humans ; Lopinavir/therapeutic use ; Male ; Middle Aged ; Ritonavir/therapeutic use ; United States/epidemiology ; United States Food and Drug Administration
Czasopismo naukowe
Tytuł :
Pharmacokinetics, Safety, and Tolerability of Ravidasvir, with and without Danoprevir/Ritonavir, in Healthy Subjects.
Autorzy :
Wu G; Research Center of Clinical Pharmacy, State Key Laboratory for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.; Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zhou H; Research Center of Clinical Pharmacy, State Key Laboratory for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.; Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Wu J; Zhejiang University School of Medicine, Hangzhou, China.
Lv D; Research Center of Clinical Pharmacy, State Key Laboratory for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.; Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Wu L; Research Center of Clinical Pharmacy, State Key Laboratory for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.; Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zhai Y; Research Center of Clinical Pharmacy, State Key Laboratory for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.; Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Lin M; Research Center of Clinical Pharmacy, State Key Laboratory for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.; Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Wu JJ; Ascletis Bioscience Co., Ltd., Hangzhou, China.
Shentu J; Research Center of Clinical Pharmacy, State Key Laboratory for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.; Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Pokaż więcej
Źródło :
Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2021 Sep 17; Vol. 65 (10), pp. e0060021. Date of Electronic Publication: 2021 Jul 12.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Lactams*
Ritonavir*/adverse effects
Adult ; Area Under Curve ; Benzimidazoles ; Cyclopropanes ; Healthy Volunteers ; Humans ; Isoindoles ; Lactams, Macrocyclic ; Proline/analogs & derivatives ; Sulfonamides ; Valine/analogs & derivatives
Czasopismo naukowe
Tytuł :
Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital.
Autorzy :
Gourieux B; Pharmacy, Hopitaux universitaires de Strasbourg, Strasbourg, Alsace, France.
Reisz F; Service de Pharmacie, Hopitaux universitaires de Strasbourg, Strasbourg, Alsace, France.
Belmas AS; Service de Pharmacie, Hopitaux universitaires de Strasbourg, Strasbourg, Alsace, France.
Danion F; Service des Maladies infectieuses et tropicales, Hopitaux universitaires de Strasbourg, Strasbourg, Alsace, France.
Fourtage M; Service de Pharmacie, Hopitaux universitaires de Strasbourg, Strasbourg, Alsace, France.
Nai T; Service de Pharmacie, Hopitaux universitaires de Strasbourg, Strasbourg, Alsace, France.
Reiter-Schatz A; Service de Pharmacie, Hopitaux universitaires de Strasbourg, Strasbourg, Alsace, France.
Ruch Y; Service des Maladies infectieuses et tropicales, Hopitaux universitaires de Strasbourg, Strasbourg, Alsace, France.
Walther J; Service de Pharmacie, Hopitaux universitaires de Strasbourg, Strasbourg, Alsace, France.
Nivoix Y; Service de Pharmacie, Hopitaux universitaires de Strasbourg, Strasbourg, Alsace, France.
Michel B; Service de Pharmacie, Hopitaux universitaires de Strasbourg, Strasbourg, Alsace, France .
Pokaż więcej
Źródło :
European journal of hospital pharmacy : science and practice [Eur J Hosp Pharm] 2021 Sep; Vol. 28 (5), pp. 242-247. Date of Electronic Publication: 2020 Nov 25.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Pandemics*
Antiviral Agents/*therapeutic use
Azithromycin/*therapeutic use
COVID-19/*drug therapy
Drug Prescriptions/*statistics & numerical data
Hospitals, Teaching/*statistics & numerical data
Hydroxychloroquine/*therapeutic use
Lopinavir/*therapeutic use
Ritonavir/*therapeutic use
Adult ; Aged ; Antiviral Agents/adverse effects ; Azithromycin/adverse effects ; Drug Combinations ; Female ; France ; Humans ; Hydroxychloroquine/adverse effects ; Lopinavir/adverse effects ; Male ; Middle Aged ; Patient Safety ; Pharmacists ; Physicians ; Retrospective Studies ; Ritonavir/adverse effects
Czasopismo naukowe
Tytuł :
Comparative therapeutic efficacy of interferon alfa-2b and combination lopinavir/ritonavir plus interferon alfa-2b against SARS-CoV-2.
Autorzy :
Liu J; Department of Critical Care Medicine, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshundong Street, Chaoyang District, Beijing, 100015, People's Republic of China.
Du C; Department of Critical Care Medicine, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshundong Street, Chaoyang District, Beijing, 100015, People's Republic of China.
Pu L; Department of Critical Care Medicine, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshundong Street, Chaoyang District, Beijing, 100015, People's Republic of China.
Xiang P; Department of Critical Care Medicine, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshundong Street, Chaoyang District, Beijing, 100015, People's Republic of China.
Xiong H; Department of Critical Care Medicine, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshundong Street, Chaoyang District, Beijing, 100015, People's Republic of China.
Xie W; Center of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China.
Chen Z; Center of Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China.
Li A; Department of Critical Care Medicine, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshundong Street, Chaoyang District, Beijing, 100015, People's Republic of China. .
Pokaż więcej
Źródło :
BMC infectious diseases [BMC Infect Dis] 2021 Aug 30; Vol. 21 (1), pp. 885. Date of Electronic Publication: 2021 Aug 30.
Typ publikacji :
Journal Article
MeSH Terms :
COVID-19*/drug therapy
Ritonavir*/therapeutic use
Adult ; Antiviral Agents/therapeutic use ; Drug Combinations ; Humans ; Interferon alpha-2 ; Lopinavir/therapeutic use ; RNA, Viral ; Retrospective Studies ; SARS-CoV-2
SCR Protocol :
COVID-19 drug treatment
Czasopismo naukowe
Tytuł :
Current evidence for the risk of PR prolongation, QRS widening, QT prolongation, from lopinavir, ritonavir, atazanavir, and saquinavir: A systematic review.
Autorzy :
Ridjab DA; School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia.
Ivan I
Budiman F
Juliawati DJ
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2021 Aug 06; Vol. 100 (31), pp. e26787.
Typ publikacji :
Journal Article; Systematic Review
MeSH Terms :
Atazanavir Sulfate/*adverse effects
Long QT Syndrome/*etiology
Lopinavir/*adverse effects
Ritonavir/*adverse effects
Saquinavir/*adverse effects
Adult ; Atazanavir Sulfate/therapeutic use ; Cytochrome P-450 CYP3A Inhibitors/adverse effects ; Drug Therapy, Combination/methods ; Drug Therapy, Combination/standards ; Electrocardiography/methods ; Humans ; Lopinavir/therapeutic use ; Ritonavir/therapeutic use ; Saquinavir/therapeutic use
Czasopismo naukowe
Tytuł :
Pharmacokinetic interactions between the potential COVID-19 treatment drugs lopinavir/ritonavir and arbidol in rats.
Autorzy :
Hu Y; Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
Zuo M; Public Service Platform for the Evaluation of Innovative Drug Property, Hangzhou 311121, China.
Wang X; Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
Wang R; Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
Li L; Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
Lu X; Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
Jiang S; Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
Pokaż więcej
Źródło :
Journal of Zhejiang University. Science. B [J Zhejiang Univ Sci B] 2021 Jul 15; Vol. 22 (7), pp. 599-602.
Typ publikacji :
Journal Article
MeSH Terms :
SARS-CoV-2*
COVID-19/*drug therapy
Indoles/*administration & dosage
Lopinavir/*administration & dosage
Ritonavir/*administration & dosage
Animals ; Drug Interactions ; Drug Therapy, Combination ; Female ; Indoles/pharmacokinetics ; Lopinavir/pharmacokinetics ; Male ; Rats ; Retrospective Studies ; Ritonavir/pharmacokinetics
SCR Protocol :
COVID-19 drug treatment
Czasopismo naukowe
Tytuł :
Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review.
Autorzy :
Joseph BA; Department of Data Research, Nested Knowledge, St. Paul, MN, USA.
Dibas M; College of Medicine, Sulaiman Al Rajhi University, Qassim, Saudi Arabia.
Evanson KW; Department of Medical Writing, Superior Medical Experts, St. Paul, MN, USA.
Paranjape G; Department of Medical Writing, Superior Medical Experts, St. Paul, MN, USA.
Vegivinti CTR; Department of General Medicine, Kasturba Medical College, Manipal Academy of Higher Education (MAHE), Manipal, India.
Selvan PT; Department of General Medicine, Kasturba Medical College, Manipal Academy of Higher Education (MAHE), Manipal, India.
Saravu K; Department of Infectious Diseases, Kasturba Medical College, Manipal Academy of Higher Education (MAHE), Manipal, India.
Gupta N; Department of Infectious Diseases, Kasturba Medical College, Manipal Academy of Higher Education (MAHE), Manipal, India.
Pulakurthi YS; Department of Internal Medicine, Kamineni Academy of Medical Sciences and Research Centre, Hyderabad, India.
Keesari PR; Department of Internal Medicine, Kamineni Academy of Medical Sciences and Research Centre, Hyderabad, India.
Varsha S; Department of Internal Medicine, Kasturba Medical College, Manipal Academy of Higher Education (MAHE), Manipal, India.
Chittajallu S; Department of Internal Medicine, Rangaraya Medical College, Kakinada, India.
Dmytriw AA; Neuroradiology & Neurointervention Service, Brigham and Women's Hospital, Harvard Medical School, Boston, USA.
Reierson NL; Department of Data Research, Nested Knowledge, St. Paul, MN, USA.
Mikoff N; Department of Data Research, Nested Knowledge, St. Paul, MN, USA.
Kamrowski S; Department of Data Research, Nested Knowledge, St. Paul, MN, USA.
Schmidt M; Department of Data Research, Nested Knowledge, St. Paul, MN, USA.
Davis AR; Department of Medical Writing, Superior Medical Experts, St. Paul, MN, USA.
Pederson JM; Department of Medical Writing, Superior Medical Experts, St. Paul, MN, USA.
Mishra HK; Department of Veterinary and Biomedical Sciences, University of Minnesota - Twin Cities, Minneapolis, MN, USA.
Touchette JC; Department of Medical Writing, Superior Medical Experts, St. Paul, MN, USA.
Kallmes K; Department of Data Research, Nested Knowledge, St. Paul, MN, USA.
Pokaż więcej
Źródło :
Expert review of anti-infective therapy [Expert Rev Anti Infect Ther] 2021 Jun; Vol. 19 (6), pp. 679-687. Date of Electronic Publication: 2020 Dec 21.
Typ publikacji :
Journal Article; Systematic Review
MeSH Terms :
Antiviral Agents/*therapeutic use
COVID-19/*drug therapy
Lopinavir/*therapeutic use
Ritonavir/*therapeutic use
SARS-CoV-2/*drug effects
Antiviral Agents/administration & dosage ; Drug Combinations ; Humans ; Lopinavir/administration & dosage ; Lopinavir/adverse effects ; Ritonavir/administration & dosage ; Ritonavir/adverse effects ; Treatment Outcome
SCR Protocol :
COVID-19 drug treatment
Czasopismo naukowe
Tytuł :
Effect of aprepitant on kynurenine to tryptophan ratio in cART treated and cART naïve adults living with HIV.
Autorzy :
Spitsin S; Children's Hospital of Philadelphia Research Institute.
Pappa V; Children's Hospital of Philadelphia Research Institute.
Kinder A; Children's Hospital of Philadelphia Research Institute.
Evans DL; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Rappaport J; Tulane National Primate Research Center, Covington, LA, USA.
Douglas SD; Children's Hospital of Philadelphia Research Institute.; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2021 Jun 11; Vol. 100 (23), pp. e25313.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Aprepitant*/administration & dosage
Aprepitant*/adverse effects
HIV Infections*/drug therapy
HIV Infections*/immunology
HIV Infections*/psychology
HIV Infections*/virology
Mood Disorders*/drug therapy
Mood Disorders*/etiology
Ritonavir*/administration & dosage
Ritonavir*/adverse effects
Neuroimmunomodulation/*drug effects
Tryptophan/*metabolism
Adult ; Anti-HIV Agents/administration & dosage ; Anti-HIV Agents/adverse effects ; CD4 Lymphocyte Count/methods ; Double-Blind Method ; Drug Therapy, Combination/adverse effects ; Drug Therapy, Combination/methods ; Female ; Humans ; Kynurenine/analysis ; Male ; Neurokinin-1 Receptor Antagonists/administration & dosage ; Neurokinin-1 Receptor Antagonists/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials.
Autorzy :
Patel TK; Department of Pharmacology, All India Institute of Medical Sciences, Gorakhpur Gorakhpur, Uttar Pradesh 273008, India. Electronic address: .
Patel PB; Department of Pharmacology, GMERS Medical College, Gotri, Vadodara, Gujarat 390021, India.
Barvaliya M; Department of Pharmacology,Government Medical College, Bhavnagar, 364001 Gujarat, India.
Saurabh MK; Department of Pharmacology, All India Institute of Medical Sciences, Deoghar, Jharkhand 814142, India.
Bhalla HL; Department of Pharmacology, All India Institute of Medical Sciences, Gorakhpur Gorakhpur, Uttar Pradesh 273008, India.
Khosla PP; Department of Pharmacology, Maharishi Markandeshwar Institute of Medical Sciences and Research, Mullana, Ambala, Haryana 133207, India.
Pokaż więcej
Źródło :
Journal of infection and public health [J Infect Public Health] 2021 Jun; Vol. 14 (6), pp. 740-748. Date of Electronic Publication: 2021 Apr 20.
Typ publikacji :
Journal Article; Systematic Review
MeSH Terms :
COVID-19*/drug therapy
Ritonavir*/adverse effects
Antiviral Agents/adverse effects ; Humans ; Lopinavir/adverse effects ; Randomized Controlled Trials as Topic ; SARS-CoV-2
SCR Protocol :
COVID-19 drug treatment
Czasopismo naukowe
Tytuł :
Aqueous Dissolution and Dispersion Behavior of Polyvinylpyrrolidone Vinyl Acetate-based Amorphous Solid Dispersion of Ritonavir Prepared by Hot-Melt Extrusion with and without Added Surfactants.
Autorzy :
Siriwannakij N; College of Pharmacy and Health Sciences, St. John's University, 8000 Utopia Parkway, Queens, NY 11439, USA.
Heimbach T; MRL - Sterile & Specialty Products Group, Biopharmaceutics, Merck & Co., 126 E Lincoln Avenue, Rahway, NJ 07065, USA.
Serajuddin ATM; College of Pharmacy and Health Sciences, St. John's University, 8000 Utopia Parkway, Queens, NY 11439, USA. Electronic address: .
Pokaż więcej
Źródło :
Journal of pharmaceutical sciences [J Pharm Sci] 2021 Apr; Vol. 110 (4), pp. 1480-1494. Date of Electronic Publication: 2020 Aug 20.
Typ publikacji :
Journal Article
MeSH Terms :
Povidone*
Ritonavir*
Drug Compounding ; Solubility ; Surface-Active Agents ; Vinyl Compounds
Czasopismo naukowe
Tytuł :
Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19.
Autorzy :
Kocayiğit H; Department of Anaesthesiology and Reanimation, Sakarya University Education and Research Hospital, Sakarya, Turkey.
Özmen Süner K; Department of Intensive Care, Sakarya University Education and Research Hospital, Sakarya, Turkey.
Tomak Y; Department of Anaesthesiology and Reanimation, Sakarya University Education and Research Hospital, Sakarya, Turkey.
Demir G; Department of Anaesthesiology and Reanimation, Sakarya University Education and Research Hospital, Sakarya, Turkey.
Yaylacı S; Department of Internal Medicine, Sakarya University Education and Research Hospital, Sakarya, Turkey.
Dheir H; Department of Nephrology, Sakarya University Education and Research Hospital, Sakarya, Turkey.
Güçlü E; Department of Infectious Diseases and Clinical Microbiology, Sakarya University Education and Research Hospital, Sakarya, Turkey.
Erdem AF; Department of Anaesthesiology and Reanimation, Sakarya University Education and Research Hospital, Sakarya, Turkey.
Pokaż więcej
Źródło :
Journal of clinical pharmacy and therapeutics [J Clin Pharm Ther] 2021 Apr; Vol. 46 (2), pp. 454-459. Date of Electronic Publication: 2020 Oct 31.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Amides*/administration & dosage
Amides*/adverse effects
COVID-19*/diagnosis
COVID-19*/drug therapy
COVID-19*/mortality
COVID-19*/physiopathology
Critical Illness*/mortality
Critical Illness*/therapy
Lopinavir*/administration & dosage
Lopinavir*/adverse effects
Pyrazines*/administration & dosage
Pyrazines*/adverse effects
Ritonavir*/administration & dosage
Ritonavir*/adverse effects
Antiviral Agents/administration & dosage ; Antiviral Agents/adverse effects ; Drug Combinations ; Female ; Humans ; Intensive Care Units/statistics & numerical data ; Length of Stay/statistics & numerical data ; Male ; Middle Aged ; Mortality ; SARS-CoV-2/isolation & purification ; Treatment Outcome ; Turkey/epidemiology
Czasopismo naukowe
Tytuł :
Drug-drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain.
Autorzy :
Cantudo-Cuenca MD; Pharmacy Unit, Hospital Universitario Virgen de Valme, Ctra. de Cádiz Km. 548,9, Seville, Spain.
Gutiérrez-Pizarraya A; Pharmacy Unit, Hospital Universitario Virgen de Valme, Ctra. de Cádiz Km. 548,9, Seville, Spain. .
Pinilla-Fernández A; Infectious Diseases and Microbiology Unit, Hospital Universitario Virgen de Valme, Avda. Bellavista s/n, 41014, Seville, Spain.
Contreras-Macías E; Pharmacy Unit, Hospital Universitario Virgen de Valme, Ctra. de Cádiz Km. 548,9, Seville, Spain.
Fernández-Fuertes M; Infectious Diseases and Microbiology Unit, Hospital Universitario Virgen de Valme, Avda. Bellavista s/n, 41014, Seville, Spain.
Lao-Domínguez FA; Pharmacy Unit, Hospital Universitario Virgen de Valme, Ctra. de Cádiz Km. 548,9, Seville, Spain.
Rincón P; Infectious Diseases and Microbiology Unit, Hospital Universitario Virgen de Valme, Avda. Bellavista s/n, 41014, Seville, Spain.
Pineda JA; Infectious Diseases and Microbiology Unit, Hospital Universitario Virgen de Valme, Avda. Bellavista s/n, 41014, Seville, Spain.
Macías J; Infectious Diseases and Microbiology Unit, Hospital Universitario Virgen de Valme, Avda. Bellavista s/n, 41014, Seville, Spain.
Morillo-Verdugo R; Pharmacy Unit, Hospital Universitario Virgen de Valme, Ctra. de Cádiz Km. 548,9, Seville, Spain.
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2021 Jun 14; Vol. 11 (1), pp. 12414. Date of Electronic Publication: 2021 Jun 14.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Interactions*
COVID-19/*drug therapy
Hydroxychloroquine/*chemistry
Lopinavir/*chemistry
Ritonavir/*chemistry
Aged ; Analgesics/chemistry ; Analgesics/therapeutic use ; COVID-19/pathology ; COVID-19/virology ; Cardiovascular Diseases/drug therapy ; Cohort Studies ; Diuretics/chemistry ; Diuretics/therapeutic use ; Female ; Humans ; Hydroxychloroquine/therapeutic use ; Lopinavir/therapeutic use ; Male ; Middle Aged ; Nervous System Diseases/drug therapy ; Polypharmacy ; Risk Factors ; Ritonavir/therapeutic use ; SARS-CoV-2/isolation & purification ; Severity of Illness Index ; Spain
Czasopismo naukowe
Tytuł :
Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: Results of a large multicenter study.
Autorzy :
Lora-Tamayo J; Internal Medicine Department, 12 de Octubre University Hospital, Research Institute Hospital 12 de Octubre 'i+12 Institute', Madrid, Spain. Electronic address: .
Maestro G; Internal Medicine Department, 12 de Octubre University Hospital, Research Institute Hospital 12 de Octubre 'i+12 Institute', Madrid, Spain.
Lalueza A; Internal Medicine Department, 12 de Octubre University Hospital, Research Institute Hospital 12 de Octubre 'i+12 Institute', Madrid, Spain.
Rubio-Rivas M; Internal Medicine Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat (Barcelona), Spain.
Villarreal Paul G; Internal Medicine Department, Gregorio Marañon University Hospital, Madrid, Spain.
Arnalich Fernández F; Internal Medicine Department, La Paz University Hospital, Madrid, Spain.
Beato Pérez JL; Internal Medicine Department, Albacete University Hospital Complex, Albacete, Spain.
Vargas Núñez JA; Internal Medicine Department, Puerta de Hierro University Hospital, Majadahonda (Madrid), Spain.
Llorente Barrio M; Internal Medicine Department, Miguel Servet Hospital, Zaragoza, Spain.
Lumbreras Bermejo C; Internal Medicine Department, 12 de Octubre University Hospital, Research Institute Hospital 12 de Octubre 'i+12 Institute', Madrid, Spain.
Pokaż więcej
Corporate Authors :
SEMI-COVID-19 Network
Źródło :
The Journal of infection [J Infect] 2021 Jun; Vol. 82 (6), pp. 276-316. Date of Electronic Publication: 2021 Feb 11.
Typ publikacji :
Letter; Comment
MeSH Terms :
COVID-19*/drug therapy
Ritonavir*/therapeutic use
Antiviral Agents/therapeutic use ; Humans ; Lopinavir/therapeutic use ; SARS-CoV-2
SCR Protocol :
COVID-19 drug treatment
Opinia redakcyjna
Tytuł :
Reply to the letter to the Editor "Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts".
Autorzy :
Simon N; APHM, INSERM, IRD, SESSTIM, Hop Sainte Marguerite, Service de Pharmacologie Clinique, CAP-TV, Aix-Marseille University, Marseille, France.
Alvarez JC; Département de Pharmacologie-Toxicologie, Hôpitaux Universitaires Paris-Ile de France-Ouest, APHP, Hôpital Raymond Poincaré, FHU Sepsis, MasSpecLab, Plateforme de spectrométrie de masse, Inserm U-1173, Université Paris Saclay (Versailles Saint Quentin-en-Yvelines), 92380, Garches, France. .
Pokaż więcej
Źródło :
European journal of clinical pharmacology [Eur J Clin Pharmacol] 2021 May; Vol. 77 (5), pp. 793-794. Date of Electronic Publication: 2020 Nov 26.
Typ publikacji :
Letter; Comment
MeSH Terms :
COVID-19*/drug therapy
Ritonavir*
Antiviral Agents/therapeutic use ; Humans ; Lopinavir ; SARS-CoV-2
SCR Protocol :
COVID-19 drug treatment
Opinia redakcyjna
Tytuł :
Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: A pilot retrospective study.
Autorzy :
Lan X
Shao C
Zeng X
Wu Z
Xu Y
Pokaż więcej
Źródło :
International journal of clinical pharmacology and therapeutics [Int J Clin Pharmacol Ther] 2021 May; Vol. 59 (5), pp. 378-385.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
COVID-19*/drug therapy
Ritonavir*/therapeutic use
Antiviral Agents/therapeutic use ; Drug Combinations ; Humans ; Indoles ; Lopinavir/therapeutic use ; Retrospective Studies ; SARS-CoV-2
SCR Protocol :
COVID-19 drug treatment
Czasopismo naukowe
Tytuł :
Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts.
Autorzy :
Cattaneo D; Unit of Clinical Pharmacology, Fatebenefratelli Sacco University Hospital, Milan, Italy. .; Gestione Ambulatoriale Politerapie (GAP) Outpatient Clinic, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy. .
Corbellino M; 3rd Division of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy.
Gervasoni C; Gestione Ambulatoriale Politerapie (GAP) Outpatient Clinic, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy.; 3rd Division of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy.
Pokaż więcej
Źródło :
European journal of clinical pharmacology [Eur J Clin Pharmacol] 2021 May; Vol. 77 (5), pp. 791-792. Date of Electronic Publication: 2020 Nov 25.
Typ publikacji :
Letter; Comment
MeSH Terms :
COVID-19*/drug therapy
Ritonavir*/pharmacology
Antiviral Agents/therapeutic use ; Humans ; Lopinavir ; SARS-CoV-2
SCR Protocol :
COVID-19 drug treatment
Opinia redakcyjna

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies